市場調査レポート

商品コード

細胞・遺伝子治療向け製造の市場規模、シェア、動向分析レポート：治療タイプ別、規模別（研究開発）、モード別、ワークフロー別（ベクター生産、セルバンキング）、地域別、セグメント別予測、2023年～2030年

Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report By Therapy Type, By Scale (R&D), By Mode, By Workflow (Vector Production, Cell Banking), By Region, And Segment Forecasts, 2023 - 2030

出版日: 2023年01月02日 | 発行: Grand View Research

| ページ情報: 英文 217 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

Unprintable PDF (Single User License)

USD 5,950 931,353円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷もできません。

Printable PDF (5-User License)

USD 6,950 1,087,883円

レポートPDFを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

Printable PDF (Enterprise License)

USD 8,950 1,400,943円

レポートPDFの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.53円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

細胞・遺伝子治療向け製造の市場成長と動向

グランドビューリサーチ社の最新レポートによると、細胞・遺伝子治療向け製造の世界市場規模は、2030年までに471億米ドルに達すると予測されています。この市場は、臨床パイプラインの急速な進展と、先端治療に対する規制当局の承認件数の増加により、2023年から2030年にかけてCAGR26.6%を記録すると予測されており、これが市場成長の主な要因となっています。

政府当局や主要な市場参加者による多額の投資も、細胞・遺伝子治療向け製造の成長を後押しする要因となっています。過去10年間、企業によって遺伝子治療に約23億米ドルが投資されました。CDMO/CMOや自社製造業者を含む主要なサービスプロバイダーは、これらの治療法を活発な投資分野とみなしています。例えば、2020年5月、サーモフィッシャーサイエンティフィックも、ウイルスベクター製造能力を2倍に拡大するために1億8000万米ドルを投資しています。これらのプレイヤーは、製造能力の構築および/または拡大、あるいは競合他社との戦略的提携のいずれかに多額の投資を行い、市場での存在感を高めています。したがって、これらの要因は、この市場の主要な促進要因として作用すると予想されます。

臨床試験に入り、その後規制機関から販売認可を得る細胞および遺伝子治療薬の数は年々増加しています。2019年末までに、17の細胞および遺伝子治療製品が米国FDAによって商業利用を承認されました。米国FDAは、2020年初めから毎年200件以上の遺伝子・細胞治療INDを受領すると見込んでいます。また、同規制機関は2025年以降、年間最大20製品を承認する予定です。このような政府の支援的な取り組みにより、近い将来、細胞・遺伝子治療向け製造サービスの需要が高まると予想されます。

2020年3月に発表された記事によると、米国では、パイプライン（第III相試験）にある細胞・遺伝子治療薬の数は、2019年初めには289件でしたが、2020年初めには362件に達しています。前臨床パイプラインを考慮すると、その数は2倍になると予想されます。この数の増加は、細胞・遺伝子治療薬の製造サービスに対する需要の高さを示しています。America's Biopharmaceutical Companiesのレポートによると、遺伝子療法と細胞療法は、神経疾患、遺伝性疾患、がんなどの幅広い疾患に焦点を当てた臨床開発の初期から後期までの段階を経ているとのことです。

細胞・遺伝子治療向け製造市場のレポートハイライト

細胞治療向け製造部門が2022年の市場を収益面で支配しました。進行中の臨床試験の数が増え、この分野での研究が増加していることが、このセグメントの優位性につながっている

プレコマーシャルスケールの段階にある候補分子の数が多いことが、2022年のプレコマーシャルスケール製造市場セグメントの最大収益シェアに寄与している

遺伝子治療および細胞治療製品の規制当局による承認数の増加に伴い、これらの治療法の商業生産の需要が急速に増加しており、それによって商業規模製造セグメントのシェアが増加している

多くのバイオメーカーが効率的かつ迅速な製品開発のためにCMOを利用していることから、受託製造部門は予測期間中に有利な成長を遂げると予想されます。

さらに、臨床パイプラインの継続的な増加も、受託製造分野の成長を加速させる要因のひとつと考えられています。

遺伝子治療に関連する研究開発の進展と地域政府による投資の増加により、北米が収益面で世界市場を独占しています。

予測期間中、アジア太平洋地域が最も速い速度で成長すると予想されます。

この背景には、承認の迅速化、民間および政府による投資の増加、ヘルスケアニーズの高まりがあります。

調査手法
調査の仮定
調査手法
情報調達
- 購入したデータベース
- Gvrの内部データベース
- 二次情報
- 1次調査
- 1次調査の詳細
情報またはデータ分析
- データ分析モデル
市場の策定と検証
モデルの詳細
- コモディティフロー分析
  - アプローチ1：コモディティフローアプローチ
  - アプローチ2：ボトムアップアプローチを使用した国別の市場推定
市場：CAGR計算
二次情報一覧
目的

第2章エグゼクティブサマリー

競合環境
セグメントの見通し
2022年の市場概要（100万米ドル）

第3章市場変数、動向、および範囲

市場セグメンテーション
親市場系統
アンシラリー市場系統
治療タイプの浸透と成長の見通しマッピング、2022
市場力学
- 市場促進要因分析
  - 細胞および遺伝子治療の成長するパイプライン
  - 協力的な規制機関
  - 政府および民間企業別投資の増加
- 市場抑制要因分析
  - 製造に伴う技術的課題
  - 高い製造コスト
- 市場機会分析
  - 成長する市場の需要に対応するための医薬品開発者/製造業者への圧力の高まり
  - アジア太平洋やラテンアメリカなどの潜在的な市場での拡大
- 市場課題分析
  - 製造能力の不足
SWOT分析;要因別（政治と法律、経済、技術）
ポーターのファイブフォース分析
主要取引と戦略的提携分析
- 合併と買収
- 技術協力
- ライセンシングとパートナーシップ
COVID-19影響分析
- 課題分析
- 機会分析
- 主な発展と活動

第4章メーカーに焦点を当てる

細胞および遺伝子治療の製造
- 細胞・遺伝子治療施設の拡張
- 主要取引と戦略的提携分析
- 合併と買収
- 技術的なコラボレーションとパートナーシップ
- 製品の承認と発売
細胞および遺伝子治療薬の製造における原価分析
- 商品分析の全体的なコスト
- 原材料
- 人件費
- プロセスコスト
- コストモデル
- キャンペーンモデル
- 日割りモデル
- ハイブリッドモデル
- 技法別の商品原価分析
- 材料
- 装置
- 人事
- 施設

第5章治療タイプのビジネス分析

細胞および遺伝子治療向け製造市場：治療タイプの変動分析
細胞療法の製造
- 幹細胞療法
- 非幹細胞療法
遺伝子治療向け製造

第6章製造規模のビジネス分析

細胞および遺伝子治療向け製造市場：規模の変動分析
商用前/R&D規模の製造
商業規模の製造

第7章モードのビジネス分析

細胞および遺伝子治療向け製造市場：モード変動分析
受託製造
- 受託製造の細胞および遺伝子治療向け製造市場、2018年から2030年（100万米ドル）（数量、投与回数）
社内製造
- 自社製造の細胞および遺伝子治療向け製造市場、2018年から2030年（百万米ドル）（数量、投与回数）

第8章ワークフローのビジネス分析

細胞および遺伝子治療向け製造市場：ワークフローの変動分析
細胞処理
セルバンキング
プロセス開発
フィルアンドフィニッシュオペレーション
分析および品質試験
原材料試験
ベクター制作
その他

第9章地域のビジネス分析

北米
- SWOT分析
- 米国
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- カナダ
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
欧州
- SWOT分析
- ドイツ
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- 英国
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- フランス
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- イタリア
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- スペイン
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- デンマーク
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- スウェーデン
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- ノルウェー
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
アジア太平洋地域
- SWOT分析
  - 主要な地域のダイナミクス
- 日本
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- 中国
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- インド
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- 韓国
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- オーストラリア
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- タイ
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
ラテンアメリカ
- SWOT分析：
- 主な地域のダイナミクス
- ブラジル
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- メキシコ
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- アルゼンチン
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
中東およびアフリカ（MEA）
- SWOT分析
- 主な地域のダイナミクス
- 南アフリカ
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- サウジアラビア
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- アラブ首長国連邦
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- クウェート
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ

第10章競合情勢

戦略のフレームワーク
市場参入の分類
企業プロファイル
- Thermo Fisher Scientific, Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Merck Kgaa
  - 会社概要
  - Milliporesigma
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Lonza
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Catalent, Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Takara Bio, Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- F. Hoffmann-La Roche Ltd.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Wuxi Advanced Therapies
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Samsung
  - 会社概要
  - Samsung Biologics
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Boehringer Ingelheim International Gmbh
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Novartis Ag
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Hitachi Chemical Co., Ltd.（Showa Denko Materials Co Ltd）
  - 会社概要
  - Apceth Biopharma
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Cellular Therapeutics
  - 会社概要
  - 製品のベンチマーク
- Miltenyi Biotech
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Bluebird Bio Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
主要企業別：最近の進展と影響分析
企業マッピング
ベンダー情勢
- 主要なディストリビューターとチャネルパートナーのリスト
- 主要企業の市場シェア分析、2022年
公開企業
- 会社の市況分析
- 競合ダッシュボード分析
非公開企業
- 主要な新興企業のリスト
- 地域ネットワークマップ
- 会社の市況分析

図表

List of Tables

Table 1 List of secondary sources
Table 2 CMO Investments in API Biologics - Cell, Gene, Vaccine, and Virus, April - July 2020
Table 3 FDA approved Cellular and Gene Therapy Products as of July 2020
Table 4 Cell and Gene Therapy Products approved in the European Union
Table 5 Summary of risk factors associated with COVID-19 transmission in cell and gene therapy manufacturing
Table 6 Impact Analysis
Table 7 List of cell therapy manufacturers:
Table 8 List of potential end-users
Table 9 List of emerging players
Table 10 List of market differentiators
Table 11 Competitive dashboard analysis
Table 12 Regional network map
Table 13 Top cell therapy companies of 2022
Table 14 Testing methods
Table 15 Best Practices for the effective control of raw material
Table 16 Operating CMOs/ CDMOs for cell and gene therapy manufacturing in the North America
Table 17 Cell and Gene Therapy Manufacturing Capacity in North America as of 2018
Table 18 Operating CMOs/ CDMOs for cell and gene therapy manufacturing in the EU
Table 19 Cell & Gene Therapy Manufacturing Capacities in Europe 2017
Table 20 Distribution of cleanroom footprint, and QC footprint across the U.K.
Table 21 Aggregated total number of cellular therapy product manufacturing facilities, GMP laboratories, manufacturing and quality staff, parallel processes and projects by country and state/region.
Table 22 Noteworthy regenerative medicine CMOs in operation in Japan
Table 23 North America cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 24 North America cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 25 North America cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 26 North America cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 27 North America cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 28 U.S. cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 29 U.S. cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 30 U.S. cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 31 U.S. cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 32 U.S. cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 33 Canada cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 34 Canada cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 35 Canada cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 36 Canada cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 37 Canada cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 38 Europe cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 39 Europe cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 40 Europe cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 41 Europe cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 42 Europe cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 43 Germany cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 44 Germany cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 45 Germany cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 46 Germany cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 47 Germany cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 48 U.K. cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 49 U.K. cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 50 U.K. cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 51 U.K. cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 52 U.K. cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 53 Italy cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 54 Italy cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 55 Italy cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 56 Italy cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 57 Italy cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 58 France cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 59 France cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 60 France cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 61 France cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 62 France cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 63 Spain cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 64 Spain cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 65 Spain cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 66 Spain cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 67 Spain cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 68 Denmark cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 69 Denmark cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 70 Denmark cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 71 Denmark cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 72 Denmark cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 73 Sweden cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 74 Sweden cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 75 Sweden cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 76 Sweden cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 77 Sweden cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 78 Norway cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 79 Norway cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 80 Norway cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 81 Norway cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 82 Norway cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 83 Asia Pacific cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 84 Asia Pacific cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 85 Asia Pacific cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 86 Asia Pacific cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 87 Asia Pacific cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 88 Japan cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 89 Japan cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 90 Japan cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 91 Japan cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 92 Japan cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 93 China cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 94 China cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 95 China cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 96 China cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 97 China cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 98 India cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 99 India cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 100 India cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 101 India cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 102 India cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 103 South Korea cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 104 South Korea cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 105 South Korea cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 106 South Korea cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 107 South Korea cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 108 Thailand cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 109 Thailand cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 110 Thailand cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 111 Thailand cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 112 Thailand cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 113 Australia cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 114 Australia cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 115 Australia cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 116 Australia cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 117 Australia cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 118 Latin America cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 119 Latin America cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 120 Latin America cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 121 Latin America cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 122 Latin America cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 123 Brazil cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 124 Brazil cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 125 Brazil cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 126 Brazil cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 127 Brazil cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 128 Mexico cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 129 Mexico cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 130 Mexico cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 131 Mexico cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 132 Mexico cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 133 Argentina cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 134 Argentina cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 135 Argentina cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 136 Argentina cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 137 Argentina cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 138 MEA cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 139 MEA cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 140 MEA cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 141 MEA cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 142 MEA cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 143 South Africa cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 144 South Africa cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 145 South Africa cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 146 South Africa cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 147 South Africa cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 148 Saudi Arabia cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 149 Saudi Arabia cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 150 Saudi Arabia cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 151. Saudi Arabia cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 152 Saudi Arabia cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 153 UAE cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 154 UAE cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 155 UAE cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 156 UAE cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 157 UAE cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 158 Kuwait cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 159 Kuwait cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
Table 160 Kuwait cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
Table 161 Kuwait cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Table 162 Kuwait cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Medicines in development, by disease
Fig. 9 Classification of companies
Fig. 10 Cell and gene therapy manufacturing market snapshot, 2022 (USD Million)
Fig. 11 Cell & gene therapy manufacturing market segmentation
Fig. 12 Market dynamics
Fig. 13 Market driver relevance analysis (Current & future impact)
Fig. 14 Most common therapeutic areas targeted by cell therapies in development
Fig. 15 Gene therapy clinical trials number as of 2021
Fig. 16 Regenerative medicine clinical trials
Fig. 17 Expedited approval pathway designations by technology
Fig. 18 Market restraint relevance analysis (Current & future impact)
Fig. 19 Cell and gene therapy market SWOT analysis
Fig. 20 Cell and gene therapy market Porter's five forces analysis
Fig. 21 Cell therapy manufacturing collaborations from 2014 to 2018
Fig. 22 Areas of disruption due to COVID-19 reported by respondents
Fig. 23 Global financings for Cell and Gene therapy. (USD Billion)
Fig. 24 UK cell and gene therapy manufacturing capacity, 2016 to 2019
Fig. 25 Number of gene therapy sites across gene therapy and multifunctional facilities in the UK, 2019
Fig. 26 Breakdown of CoGs per process for cell therapy manufacture
Fig. 27 Comparison of costs estimated by campaign, day rate, and hybrid models
Fig. 28 Campaign model for cell and gene therapies production
Fig. 29 Day rate model for cell and gene production
Fig. 30 Hybrid model for cell and gene therapies production
Fig. 31 The proportion of funds allocation in anti-EBV CTLs and PSCs
Fig. 32 Impact Analysis
Fig. 33 Cell and gene therapy market: Therapy type outlook and key takeaways
Fig. 34 Cell and gene therapy market: therapy type movement analysis
Fig. 35 Cell therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Fig. 36 Cell therapy manufacturing market estimates and forecast for stem cell therapy, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Fig. 37 Cell therapy manufacturing market estimates and forecast for non-stem cell therapy, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Fig. 38 Gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Fig. 39 Cell and gene therapy manufacturing market: Scale outlook and key takeaways
Fig. 40 Cell and gene therapy manufacturing market: Scale movement analysis
Fig. 41 Number of cell therapy clinical trials, by phase, 2020
Fig. 42 Number of CAR-T cell therapy clinical trials, by phase, as of September 2019
Fig. 43 Cell and gene therapy manufacturing market estimates and forecast for precommercial-scale manufacturing, 2018 - 2030 (USD Million)
Fig. 44 Cell and gene therapy manufacturing market estimates and forecast for commercial-scale manufacturing, 2018 - 2030 (USD Million)
Fig. 45 Cell and gene therapy manufacturing market: Mode outlook and key takeaways
Fig. 46 Cell and gene therapy manufacturing market: Mode movement analysis
Fig. 47 Cell and gene therapy manufacturing market for contract manufacturing, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Fig. 48 Cell and gene therapy manufacturing market for in-house manufacturing, 2018 - 2030 (USD Million) (Volume, Number of Doses)
Fig. 49 Cell and gene therapy manufacturing market: Workflow outlook and key takeaways
Fig. 50 Cell and gene therapy manufacturing market: Workflow outlook and key takeaways
Fig. 51 Cell and gene therapy manufacturing market: Workflow movement analysis
Fig. 52 Cell and gene therapy manufacturing market for cell processing, 2018 - 2030 (USD Million)
Fig. 53 Cell and gene therapy manufacturing market for cell banking, 2018 - 2030 (USD Million)
Fig. 54 Cell and gene therapy manufacturing market for process development, 2018 - 2030 (USD Million)
Fig. 55 Cell and gene therapy manufacturing market for fill and finish operations, 2018 - 2030 (USD Million)
Fig. 56 Cell and gene therapy manufacturing market for analytical and quality testing, 2018 - 2030 (USD Million)
Fig. 57 Cell and gene therapy manufacturing market for raw material testing, 2018 - 2030 (USD Million)
Fig. 58 Gene therapy manufacturing facilities: Trends & types
Fig. 59 Gene therapy clinical trials
Fig. 60 Viral vectors used in clinical trials
Fig. 61 Cell and gene therapy manufacturing market for vector production, 2018 - 2030 (USD Million)
Fig. 62 Cell and gene therapy manufacturing market for others, 2018 - 2030 (USD Million)
Fig. 63 Cell and gene therapy manufacturing market: Regional outlook and key takeaways
Fig. 64 Cell and gene therapy manufacturing market: Regional movement analysis
Fig. 65 North America cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 U.S. cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Canada cell and gene therapy manufacturing) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Europe cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Germany cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 U.K. cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 France cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Italy cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Spain cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Denmark cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Sweden cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Norway cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Asia Pacific cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Japan cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 China cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 India cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 South Korea cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Australia cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Thailand cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Latin America cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Brazil cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 Mexico cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Argentina cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Middle East & Africa cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 South Africa cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 Saudi Arabia cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 UAE cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Kuwait cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Strategy framework
Fig. 94 Market participation categorization

Product Code: GVR-4-68038-289-1

Cell And Gene Therapy Manufacturing Market Growth & Trends:

The global cell and gene therapy manufacturing market size is expected to reach USD 47.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 26.6% from 2023 to 2030 owing to the exponential progress of the clinical pipeline, coupled with a rising number of regulatory approvals for advanced therapies, which has majorly driven the growth of the market.

Significant investments by government authorities and key market players are other factors fueling the growth of cell and gene therapy manufacturing. Around USD 2.3 billion was invested in gene therapies by companies over the last decade. Major service providers, including CDMOs/CMOs and in-house manufacturers, consider these therapies as an active area of investment. For instance, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. These players are investing significant amounts either in building and/or expanding manufacturing capabilities or forming strategic alliances with competitors to boost their market presence. Thus, these factors are anticipated to act as primary driving factors for this market.

The number of cell and gene therapies entering clinical trials and later gaining marketing authorization from regulatory bodies is increasing every year. By the end of 2019, 17 cell and gene therapy products were approved by the U.S. FDA for commercial use. The U.S. FDA is expecting to receive over 200 gene and cell treatment INDs annually from the beginning of 2020. The regulatory body is also planning to approve up to 20 products per year from 2025. Such supportive government initiatives are expected to increase the demand for cell and gene therapy manufacturing services in the near future.

Following an article published in March 2020, in the U.S., the number of cell and gene therapies in the pipeline (phase III trials) was 289 at the beginning of 2019, which reached 362 in early 2020. The number is expected to increase twofold if the preclinical pipeline is considered. This growing number indicates the high demand for manufacturing services for cell and gene therapies. According to a report by America's Biopharmaceutical Companies, gene and cell therapies range from early to late stages of clinical development with a focus on a wide spectrum of diseases, including neurologic conditions, genetic disorders, and cancer.

Cell And Gene Therapy Manufacturing Market Report Highlights:

The cell therapy manufacturing segment dominated the 2022 market in terms of revenue. A growing number of ongoing clinical trials and increasing research in this space has resulted in the segment dominance

A high number of candidate molecules in the pre-commercial scale stage has contributed to the largest revenue share for the pre-commercial scale manufacturing market segment in 2022

With an increasing number of regulatory approvals for gene and cell therapy products, the demand for commercial production of these therapies is increasing rapidly, thereby increasing the share of the commercial-scale manufacturing segment

The contract manufacturing segment is expected to witness lucrative growth during the forecast period, as a substantial number of biomanufacturers are turning to CMOs for efficient and rapid product development

Moreover, the constantly growing clinical pipeline is another contributing factor expected to accelerate contract manufacturing segment growth

North America dominated the global market in terms of revenue owing to advancements in research and development pertaining to gene therapy and the increasing number of investments by the regional governments

The Asia Pacific region is anticipated to grow at the fastest rate throughout the forecast period

This can be attributed to the establishment of accelerated approval pathways, growing private and government investments, and increasing healthcare needs

Table of Content

Chapter 1 Methodology And Scope

1.1 Research Methodology
1.2 Research Assumptions
- 1.2.1 Estimates And Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
- 1.4.1 Purchased Database
- 1.4.2 Gvr's Internal Database
- 1.4.3 Secondary Sources
- 1.4.4 Primary Research
- 1.4.5 Details Of Primary Research
1.5 Information Or Data Analysis
- 1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
- 1.7.1 Commodity Flow Analysis
  - 1.7.1.1 Approach 1: Commodity Flow Approach
  - 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.8 Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 Objectives
- 1.10.1 Objective 1
- 1.10.2 Objective 2

Chapter 2 Executive Summary

2.1 Competition Milieu
2.2 Segment Outlook
2.3 Market Summary, 2022 (USD Million)

Chapter 3 Market Variables, Trends, & Scope

3.1 Market Segmentation
3.2 Parent Market Lineage
3.3 Ancillary Market Lineage
3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2022
3.5 Market Dynamics
- 3.5.1 Market Drivers Analysis
  - 3.5.1.1 Growing Pipeline Of Cell And Gene Therapy
  - 3.5.1.2 Supportive Regulatory Bodies
  - 3.5.1.3 Increase In Investment By Government And Private Players
- 3.5.2 Market Restraint Analysis
  - 3.5.2.1 Technological Challenges Associated With Manufacturing
  - 3.5.2.2 High Cost Of Manufacturing
- 3.5.3 Market Opportunity Analysis
  - 3.5.3.1 Rising Pressure On Drug Developers/Manufacturers To Meet The Growing Market Demand
  - 3.5.3.2 Expansion In Potential Markets Such As Asia Pacific And Latin America
- 3.5.4 Market Challenge Analysis
  - 3.5.4.1 Lack Of Manufacturing Capacity
3.6 Swot Analysis; By Factor (Political & Legal, Economic, And Technological)
3.7 Porter's Five Forces Analysis
3.8 Major Deals And Strategic Alliances Analysis
- 3.8.1 Mergers And Acquisitions
- 3.8.2 Technological Collaborations
- 3.8.3 Licensing And Partnerships
3.9 Covid-19 Impact Analysis
- 3.9.1 Challenge Analysis
- 3.9.2 Opportunity Analysis
- 3.9.3 Key Developments And Activities

Chapter 4 Focus On Manufacturers

4.1 Cell And Gene Therapy Manufacturing
- 4.1.1 Facility Expansion For Cell And Gene Therapies
- 4.1.2 Major Deals And Strategic Alliances Analysis
- 4.1.3 Mergers And Acquisitions
- 4.1.4 Technological Collaborations And Partnerships
- 4.1.5 Product Approvals And Launch
4.2 Cost Of Goods Analysis In Cell And Gene Therapy Manufacturing
- 4.2.1 Overall Cost Of Goods Analysis
- 4.2.2 Raw Material
- 4.2.3 Labor Costs
- 4.2.4 Process Costs
- 4.2.5 Cost Models
- 4.2.6 Campaign Model
- 4.2.7 Day Rate Model
- 4.2.8 Hybrid Model
- 4.2.9 Cost Of Goods Analysis, By Technique
- 4.2.10 Materials
- 4.2.11 Equipment
- 4.2.12 Personnel
- 4.2.13 Facility

Chapter 5 Therapy Type Business Analysis

5.1 Cell and Gene Therapy Manufacturing Market: Therapy Type Movement Analysis
5.2 Cell Therapy Manufacturing
- 5.2.1 Cell Therapy Manufacturing Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
- 5.2.2 Stem Cell Therapy
- 5.2.3 Cell Therapy Manufacturing Market Estimates And Forecast For Stem Cell Therapy, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
- 5.2.4 Non-Stem Cell Therapy
- 5.2.5 Cell Therapy Manufacturing Market Estimates And Forecast For Non-Stem Cell Therapy, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
5.3 Gene Therapy Manufacturing
- 5.3.1 Gene Therapy Manufacturing Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume, Number Of Doses)

Chapter 6 Manufacturing Scale Business Analysis

6.1 Cell And Gene Therapy Manufacturing Market: Scale Movement Analysis
6.2 Precommercial/R&D Scale Manufacturing
- 6.2.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Precommercial/R&D Scale Manufacturing, 2018 - 2030 (USD Million)
6.3 Commercial-Scale Manufacturing
- 6.3.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Commercial-Scale Manufacturing, 2018 - 2030 (USD Million)

Chapter 7 Mode Business Analysis

7.1 Cell And Gene Therapy Manufacturing Market: Mode Movement Analysis
7.2 Contract Manufacturing
- 7.2.1 Cell And Gene Therapy Manufacturing Market For Contract Manufacturing, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
7.3 In-House Manufacturing
- 7.3.1 Cell And Gene Therapy Manufacturing Market For In-House Manufacturing, 2018 - 2030 (USD Million) (Volume, Number Of Doses)

Chapter 8 Workflow Business Analysis

8.1 Cell And Gene Therapy Manufacturing Market: Workflow Movement Analysis
8.2 Cell Processing
- 8.2.1 Cell And Gene Therapy Manufacturing Market For Cell Processing, 2018 - 2030 (USD Million)
8.3 Cell Banking
- 8.3.1 Cell And Gene Therapy Manufacturing Market For Cell Banking, 2018 - 2030 (USD Million)
8.4 Process Development
- 8.4.1 Cell And Gene Therapy Manufacturing Market For Process Development, 2018 - 2030 (USD Million)
8.5 Fill And Finish Operations
- 8.5.1 Cell And Gene Therapy Manufacturing Market For Fill And Finish Operations, 2018 - 2030 (USD Million)
8.6 Analytical And Quality Testing
- 8.6.1 Cell And Gene Therapy Manufacturing Market For Analytical And Quality Testing, 2018 - 2030 (USD Million)
8.7 Raw Material Testing
- 8.7.1 Cell And Gene Therapy Manufacturing Market For Raw Material Testing, 2018 - 2030 (USD Million)
8.8 Vector Production
- 8.8.1 Cell And Gene Therapy Manufacturing Market For Vector Production, 2018 - 2030 (USD Million)
8.9 Others
- 8.9.1 Cell And Gene Therapy Manufacturing Market For Others, 2018 - 2030 (USD Million)

Chapter 9 Regional Business Analysis

9.1 North America
- 9.1.1 Swot Analysis
  - 9.1.1.1 North America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.1.2 U.S.
  - 9.1.2.1 Key Country Dynamics
  - 9.1.2.2 Target Disease Prevalence
  - 9.1.2.3 Competitive Scenario
  - 9.1.2.4 Regulatory Framework
  - 9.1.2.5 Reimbursement Scenario
  - 9.1.2.6 U.S. Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.1.3 Canada
  - 9.1.3.1 Key Country Dynamics
  - 9.1.3.2 Target Disease Prevalence
  - 9.1.3.3 Competitive Scenario
  - 9.1.3.4 Regulatory Framework
  - 9.1.3.5 Reimbursement Scenario
  - 9.1.3.6 Canada Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2 Europe
- 9.2.1 Swot Analysis
  - 9.2.1.1 Europe Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.2.2 Germany
  - 9.2.2.1 Key Country Dynamics
  - 9.2.2.2 Target Disease Prevalence
  - 9.2.2.3 Competitive Scenario
  - 9.2.2.4 Regulatory Framework
  - 9.2.2.5 Reimbursement Scenario
  - 9.2.2.6 Germany Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.2.3 U.K.
  - 9.2.3.1 Key Country Dynamics
  - 9.2.3.2 Target Disease Prevalence
  - 9.2.3.3 Competitive Scenario
  - 9.2.3.4 Regulatory Framework
  - 9.2.3.5 Reimbursement Scenario
  - 9.2.3.6 UK Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.2.4 France
  - 9.2.4.1 Key Country Dynamics
  - 9.2.4.2 Target Disease Prevalence
  - 9.2.4.3 Competitive Scenario
  - 9.2.4.4 Regulatory Framework
  - 9.2.4.5 Reimbursement Scenario
  - 9.2.4.6 France Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.2.5 Italy
  - 9.2.5.1 Key Country Dynamics
  - 9.2.5.2 Target Disease Prevalence
  - 9.2.5.3 Competitive Scenario
  - 9.2.5.4 Regulatory Framework
  - 9.2.5.5 Reimbursement Scenario
  - 9.2.5.6 Italy Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.2.6 Spain
  - 9.2.6.1 Key Country Dynamics
  - 9.2.6.2 Target Disease Prevalence
  - 9.2.6.3 Competitive Scenario
  - 9.2.6.4 Regulatory Framework
  - 9.2.6.5 Reimbursement Scenario
  - 9.2.6.6 Spain Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.2.7 Denmark
  - 9.2.7.1 Key Country Dynamics
  - 9.2.7.2 Target Disease Prevalence
  - 9.2.7.3 Competitive Scenario
  - 9.2.7.4 Regulatory Framework
  - 9.2.7.5 Reimbursement Scenario
  - 9.2.7.6 Denmark Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.2.8 Sweden
  - 9.2.8.1 Key Country Dynamics
  - 9.2.8.2 Target Disease Prevalence
  - 9.2.8.3 Competitive Scenario
  - 9.2.8.4 Regulatory Framework
  - 9.2.8.5 Reimbursement Scenario
  - 9.2.8.6 Sweden Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.2.9 Norway
  - 9.2.9.1 Key Country Dynamics
  - 9.2.9.2 Target Disease Prevalence
  - 9.2.9.3 Competitive Scenario
  - 9.2.9.4 Regulatory Framework
  - 9.2.9.5 Reimbursement Scenario
  - 9.2.9.6 Norway Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3 Asia Pacific
- 9.3.1 SWOT Analysis
  - 9.3.1.1 Key Region Dynamics
  - 9.3.1.2 Asia Pacific Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.2 Japan
  - 9.3.2.1 Target Disease Prevalence
  - 9.3.2.2 Competitive Scenario
  - 9.3.2.3 Regulatory Framework
  - 9.3.2.4 Reimbursement Scenario
  - 9.3.2.5 Japan Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.3 China
  - 9.3.3.1 Target Disease Prevalence
  - 9.3.3.2 Competitive Scenario
  - 9.3.3.3 Regulatory Framework
  - 9.3.3.4 Reimbursement Scenario
  - 9.3.3.5 China Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.4 India
  - 9.3.4.1 Target Disease Prevalence
  - 9.3.4.2 Competitive Scenario
  - 9.3.4.3 Regulatory Framework
  - 9.3.4.4 Reimbursement Scenario
  - 9.3.4.5 India Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.5 South Korea
  - 9.3.5.1 Target Disease Prevalence
  - 9.3.5.2 Competitive Scenario
  - 9.3.5.3 Regulatory Framework
  - 9.3.5.4 Reimbursement Scenario
  - 9.3.5.5 South Korea Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.3.6 Australia
  - 9.3.6.1 Target Disease Prevalence
  - 9.3.6.2 Competitive Scenario
  - 9.3.6.3 Regulatory Framework
  - 9.3.6.4 Reimbursement Scenario
  - 9.3.6.5 Australia Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.7 Thailand
  - 9.3.7.1 Target Disease Prevalence
  - 9.3.7.2 Competitive Scenario
  - 9.3.7.3 Regulatory Framework
  - 9.3.7.4 Reimbursement Scenario
  - 9.3.7.5 Thailand Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4 Latin America
- 9.4.1 Swot Analysis:
- 9.4.2 Key Regional Dynamics
  - 9.4.2.1 Latin America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.3 Brazil
  - 9.4.3.1 Target Disease Prevalence
  - 9.4.3.2 Competitive Scenario
  - 9.4.3.3 Regulatory Framework
  - 9.4.3.4 Reimbursement Scenario
  - 9.4.3.5 Brazil Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.4 Mexico
  - 9.4.4.1 Target Disease Prevalence
  - 9.4.4.2 Competitive Scenario
  - 9.4.4.3 Regulatory Framework
  - 9.4.4.4 Reimbursement Scenario
  - 9.4.4.5 Mexico Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.5 Argentina
  - 9.4.5.1 Target Disease Prevalence
  - 9.4.5.2 Competitive Scenario
  - 9.4.5.3 Regulatory Framework
  - 9.4.5.4 Reimbursement Scenario
  - 9.4.5.5 Argentina Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5 Middle East & Africa (MEA)
- 9.5.1 Swot Analysis
- 9.5.2 Key Regional Dynamics
  - 9.5.2.1 Middle East & Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.3 South Africa
  - 9.5.3.1 Target Disease Prevalence
  - 9.5.3.2 Competitive Scenario
  - 9.5.3.3 Regulatory Framework
  - 9.5.3.4 Reimbursement Scenario
  - 9.5.3.5 South Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.4 Saudi Arabia
  - 9.5.4.1 Target Disease Prevalence
  - 9.5.4.2 Competitive Scenario
  - 9.5.4.3 Regulatory Framework
  - 9.5.4.4 Reimbursement Scenario
  - 9.5.4.5 Saudi Arabia Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.5 UAE
  - 9.5.5.1 Target Disease Prevalence
  - 9.5.5.2 Competitive Scenario
  - 9.5.5.3 Regulatory Framework
  - 9.5.5.4 Reimbursement Scenario
  - 9.5.5.5 UAE Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.6 Kuwait
  - 9.5.6.1 Target Disease Prevalence
  - 9.5.6.2 Competitive Scenario
  - 9.5.6.3 Regulatory Framework
  - 9.5.6.4 Reimbursement Scenario
  - 9.5.6.5 Kuwait Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Competitive Landscape

10.1 Strategy Framework
10.2 Market Participation Categorization
10.3 Company Profiles
- 10.3.1 Thermo Fisher Scientific, Inc.
  - 10.3.1.1 Company Overview
  - 10.3.1.2 Financial Performance
  - 10.3.1.3 Product Benchmarking
  - 10.3.1.4 Strategic Initiatives
- 10.3.2 Merck Kgaa
  - 10.3.2.1 Company Overview
  - 10.3.2.1.1 Milliporesigma
  - 10.3.2.2 Financial Performance
  - 10.3.2.3 Product Benchmarking
  - 10.3.2.4 Strategic Initiatives
- 10.3.3 Lonza
  - 10.3.3.1 Company Overview
  - 10.3.3.2 Financial Performace
  - 10.3.3.3 Product Benchmarking
  - 10.3.3.4 Strategic Initiatives
- 10.3.4 Catalent, Inc.
  - 10.3.4.1 Company Overview
  - 10.3.4.2 Financial Performance
  - 10.3.4.3 Product Benchmarking
  - 10.3.4.4 Strategic Initiatives
- 10.3.5 Takara Bio, Inc.
  - 10.3.5.1 Company Overview
  - 10.3.5.2 Financial Performance
  - 10.3.5.3 Product Benchmarking
  - 10.3.5.4 Strategic Initiatives
- 10.3.6 F. Hoffmann-La Roche Ltd.
  - 10.3.6.1 Company Overview
  - 10.3.6.2 Financial Performance
  - 10.3.6.3 Product Benchmarking
  - 10.3.6.4 Strategic Initiatives
- 10.3.7 Wuxi Advanced Therapies
  - 10.3.7.1 Company Overview
  - 10.3.7.2 Financial Performance
  - 10.3.7.3 Product Benchmarking
  - 10.3.7.4 Strategic Initiatives
- 10.3.8 Samsung
  - 10.3.8.1 Company Overview
  - 10.3.8.1.1 Samsung Biologics
  - 10.3.8.2 Company Overview
  - 10.3.8.3 Financial Performance
  - 10.3.8.4 Product Benchmarking
  - 10.3.8.5 Strategic Initiatives
- 10.3.9 Boehringer Ingelheim International Gmbh
  - 10.3.9.1 Company Overview
  - 10.3.9.2 Financial Performance
  - 10.3.9.3 Product Benchmarking
  - 10.3.9.4 Strategic Initiatives
- 10.3.10 Novartis Ag
  - 10.3.10.1 Company Overview
  - 10.3.10.2 Financial Performance
  - 10.3.10.3 Product Benchmarking
  - 10.3.10.4 Strategic Initiatives
- 10.3.11 Hitachi Chemical Co., Ltd. (Showa Denko Materials Co Ltd)
  - 10.3.10.1 Company Overview
  - 10.3.10.1.1 Apceth Biopharma
  - 10.3.10.2 Company Overview
  - 10.3.10.3 Financial Performance
  - 10.3.10.4 Product Benchmarking
  - 10.3.10.5 Strategic Initiatives
- 10.3.12 Cellular Therapeutics
  - 10.3.12.1 Company Overview
  - 10.3.12.2 Product Benchmarking
- 10.3.13 Miltenyi Biotech
  - 10.3.13.1 Company Overview
  - 10.3.13.2 Financial Performance
  - 10.3.13.3 Product Benchmarking
  - 10.3.13.4 Strategic Initiatives
- 10.3.14 Bluebird Bio Inc.
  - 10.3.14.1 Company Overview
  - 10.3.14.2 Financial Performance
  - 10.3.14.3 Product Benchmarking
  - 10.3.14.4 Strategic Initiatives
10.4 Recent Developments And Impact Analysis By Key Market Participants
10.5 Company Mapping
10.6 Vendor Landscape
- 10.6.1 List Of Key Distributors And Channel Partners
- 10.6.2 Key Company Market Share Analysis, 2022
10.7 Public Companies
- 10.7.1 Company Market Position Analysis
- 10.7.2 Competitive Dashboard Analysis
10.8 Private Companies
- 10.8.1 List Of Key Emerging Companies
- 10.8.2 Regional Network Map
- 10.8.3 Company Market Position Analysis